Sardocor (Medera Biopharma)
AAV1/SERCA2a gene therapy for heart failure
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | SERCA2a (gene therapy)Gene therapy / editing | Heart Failure |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.